Biocon’s Itolizumab Gets DCGI Approval For COVID-19 Treatment
Posted by
www.biotecnika.org
Biocon's Itolizumab Gets DCGI Approval For COVID-19 Treatment The
Drugs Controller General of India (DCGI) approved the use of Biocon's
biologic drug Itolizumab for the treatment of moderate to severe novel
coronavirus patients. Biocon said in a BSE filing that DCGI had
approved the use of Itolizumab injection 25mg/5mL solution in India
for emergency treatment […]
The post Biocon's Itolizumab Gets DCGI Approval For COVID-19 Treatment
appeared first on BioTecNika .
https://www.biotecnika.org/2020/07/itolizumab-for-covid-19-treatment-by-biocon-received-dcgi-approval/
Biotech News
Subscribe to:
Post Comments (Atom)
Post a Comment